Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial

[1]  A. Unterberg,et al.  Neurochirurgie , 2016, Anästhesie und Intensivmedizin für die Fachpflege.

[2]  Mark D. Johnson,et al.  Chemotherapy administration directly into the fourth ventricle in a nonhuman primate model. , 2012, Journal of neurosurgery. Pediatrics.

[3]  C. Petito,et al.  Safety and pharmacokinetic analysis of methotrexate administered directly into the fourth ventricle in a piglet model , 2010, Journal of Neuro-Oncology.

[4]  J. Landrum,et al.  Pharmacokinetic analysis of etoposide distribution after administration directly into the fourth ventricle in a piglet model , 2010, Journal of Neuro-Oncology.

[5]  J. Landrum,et al.  Chemotherapy administration directly into the fourth ventricle in a new piglet model. Laboratory Investigation. , 2008, Journal of neurosurgery. Pediatrics.

[6]  T. Pietsch,et al.  Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. , 2005, The New England journal of medicine.

[7]  U. Jaehde,et al.  Pharmacokinetics Following Intraventricular Administration of Chemotherapy in Patients with Neoplastic Meningitis , 2005, Clinical Pharmacokinetics.

[8]  D. Prayer,et al.  Feasibility of Long-Term Intraventricular Therapy with Mafosfamide (n = 26) and Etoposide (n = 11): Experience in 26 Children With Disseminated Malignant Brain Tumors , 2003, Journal of Neuro-Oncology.

[9]  M. Bilsky,et al.  Ommaya reservoirs for the treatment of leptomeningeal metastases. , 2000, Neurosurgery.

[10]  L. Deangelis.  Current diagnosis and treatment of leptomeningeal metastasis , 1998, Journal of Neuro-Oncology.

[11]  J. Hainfellner,et al.  Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination , 1998, Journal of Neuro-Oncology.

[12]  M. Chamberlain,et al.  Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. , 1997, Journal of neurosurgery.

[13]  A. Shuper,et al.  Cure of recurrent medulloblastoma , 1997, Cancer.

[14]  M. List,et al.  The measurement of performance in childhood cancer patients , 1987, Cancer.

[15]  H D Suit,et al.  Impact of improved local control on survival. , 1986, International journal of radiation oncology, biology, physics.

[16]  M. Leavens,et al.  Ommaya reservoirs in 387 cancer patients , 1985, Neurology.

[17]  J. Simpson,et al.  Cerebellar medulloblastoma: the importance of posterior fossa dose to survival and patterns of failure. , 1982, International journal of radiation oncology, biology, physics.

[18]  A. Spence,et al.  The ommaya reservoir. Newly recognized complications and recommendations for insertion and use , 1978, Cancer.

[19]  J. Posner,et al.  Treatment of meningeal neoplasms. , 1977, Cancer treatment reports.

[20]  W. Shapiro,et al.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. , 1975, The New England journal of medicine.

[21]  M. Herman,et al.  Disseminated necrotizing leukoencephalopathy: A complication of treated central nervous system leukemia and lymphoma , 1975, Cancer.

[22]  R. Murphy,et al.  Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration , 2000, Cancer Chemotherapy and Pharmacology.

[23]  M. Lanteri-Minet,et al.  [Neurologic complications of chemotherapy]. , 1999, La Revue de medecine interne.

[24]  P. Jenkins,et al.  Hip complications following chemoradiotherapy. , 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

[25]  G. Milbouw,et al.  [Practical assessment of brain dysfunction in severe head trauma (author's transl)]. , 1982, Neuro-Chirurgie.

[26]  P. Clifford,et al.  The Ommaya reservoir in chemotherapy for malignant disease in the CNS. , 1981, Clinical oncology.